<DOC>
	<DOCNO>NCT00002226</DOCNO>
	<brief_summary>The purpose study see safe effective give SU5416 HIV-infected patient AIDS-related Kaposi 's sarcoma ( KS ) . SU5416 may prevent growth KS tumor .</brief_summary>
	<brief_title>Safety Effectiveness Giving SU5416 HIV-Infected Patients With AIDS-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>Groups 3-6 patient sequentially assign receive escalating dos SU5416 33 % increment . Study drug administer twice-weekly intravenous injection 4 week . In absence unacceptable toxicity , respond patient may continue SU5416 4-week treatment cycle maximum 1 year presence unacceptable toxicity tumor progression .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are least 18 year old . Are HIVpositive . Have KS least 5 skin lesion . Have stable condition least 6 week prior study entry , receive antiretroviral therapy . Agree use effective method birth control study . Exclusion Criteria You eligible study : Have surgery within 4 week study entry . Have take certain medication , include therapy KS , within 3 week prior study entry . Have pulmonary KS ( KS lung ) . Have certain serious medical condition , include liver kidney problem , certain infection , certain cancer . Are allergic Cremophor . Have recover previous cancer treatment ( chemotherapy , radiotherapy , immunotherapy ) . Are pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2000</verification_date>
	<keyword>Skin Neoplasms</keyword>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Antineoplastic Agents</keyword>
</DOC>